866-997-4948(US-Canada Toll Free)

Influenza Vaccines - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 46 Pages


GlobalData, the industry analysis specialist, has released its new report, Influenza Vaccines Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Influenza Vaccines market. The report identifies the key trends shaping and driving the global Influenza Vaccines market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Influenza Vaccines sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

GlobalData estimated the global influenza vaccines market to be worth $2.8 billion in 2009. It is forecast to grow at a CAGR of 8% to reach $5 billion by 2017. This high growth forecast is primarily attributed to an increase in the patient population as a result of the increasing world population, and the need to get vaccinated each year. This growth will be further supported by increased production capacities of companies to cater to the rising demand. The strong product pipeline will complement the existing products by providing effective treatment options

Scope

The scope of the report includes: 

  • Annualized global Influenza Vaccines market revenue data from 2001 to 2009, forecast for eight years to 2017. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall in five major vaccine classes: inactivated vaccine, live attenuated vaccine, DNA vaccine, antigenic vaccine and others. Pipeline analysis covers the vaccines which are in early or late stage of development for Influenza.
  • Analysis of the current and future market competition in the global Influenza Vaccines market. The key future market players covered are Novartis, CSL Limited, MedImmune, GSK and Sanofi Aventis. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Influenza Vaccines market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Influenza Vaccines market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Influenza Vaccines market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global Influenza Vaccines market landscape? Identify, understand and capitalize
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Influenza Vaccines: Introduction 6
2.1 Guidelines for the Administration of Influenza Vaccines 6
2.2 GlobalData Pipeline Report Guidance 6

3 Influenza Vaccines: Market Characterization 8
3.1 Influenza Vaccines Market Size 8
3.2 Influenza Vaccines Market Forecast and CAGR 9
3.3 Drivers and Barriers for Influenza Vaccines Market 10
3.3.1 Drivers for Influenza Vaccines Market 10
3.3.2 Barriers for Influenza Vaccines Market 10
3.4 Opportunity and Unmet Need 11
3.5 Key Takeaway 12

4 Influenza Vaccines Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Vaccines in the Influenza Market 14
4.3.1 Fluzone 14
4.3.2 Flumist 15
4.3.3 Fluarix 15
4.3.4 Fluvirin 16
4.3.5 FluLaval 17
4.3.6 Optaflu 18
4.3.7 Intanza / IDFlu 19
4.4 Comparison of the Major Marketed Products in the Influenza Vaccines Market 20
4.5 Key Takeaway 20

5 Influenza Vaccines Market: Pipeline Assessment 21
5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytical Framework 21
5.3 Influenza Vaccines Promising Vaccines under Clinical Development 22
5.4 Molecule Profiles for Promising Vaccines under Clinical Development 23
5.4.1 Optaflu 23
5.4.2 Intanza / IDFlu 24
5.4.3 GSK2186877A 24
5.5 Influenza Vaccines Market Clinical Pipeline by Type of Vaccine 26
5.6 Influenza Vaccines Pipeline Pipeline by Clinical Phase of Development 26
5.6.1 Influenza Vaccines Phase III Clinical Pipeline 27
5.6.2 Influenza Vaccines Phase II Clinical Pipeline 27
5.6.3 Influenza Vaccines Phase I Clinical Pipeline 28
5.6.4 Influenza Vaccines Preclinical Pipeline 29
5.6.5 Influenza Vaccines Discovery Pipeline 29
5.7 Discontinued / Suspended Vaccines for Influenza 30
5.8 Key Takeaway 30

6 Global Influenza Vaccines Market: Implications for Future Market Competition 31

7 Global Influenza Vaccines Market: Future Players in the Influenza Vaccines Market 32
7.1 Introduction 32
7.2 Novartis 32
7.2.1 Company Overview 32
7.2.2 Business Description 33
7.2.3 Infectious Diseases Vaccines Pipeline 33
7.2.4 Influenza Vaccines Pipeline 34
7.3 GlaxoSmithKline 34
7.3.1 Company Overview 34
7.3.2 Business Description 34
7.3.3 Infectious Diseases Vaccines Pipeline 35
7.3.4 Influenza Vaccines Pipeline 35
7.4 Sanofi-aventis 36
7.4.1 Company Overview 36
7.4.2 Business Description 36
7.4.3 Infectious Diseases Vaccines Pipeline 37
7.4.4 Influenza Vaccines Pipeline 37
7.5 CSL Limited 37
7.5.1 Company Overview 37
7.5.2 Business Description 37
7.5.3 Infectious Diseases Vaccines Pipeline 38
7.5.4 Influenza Vaccines Pipeline 38
7.6 MedImmune 39
7.6.1 Company Overview 39
7.6.2 Business Description 39
7.6.3 Infectious Diseases Vaccines Pipeline 40
7.6.4 Influenza Vaccines Pipeline 40

8 Global Influenza Vaccines Market: Appendix 41
8.1 Market Definitions 41
8.2 Scope of Pipeline Research 41
8.3 Abbreviations 41
8.4 Research Methodology 41
8.4.1 Coverage 42
8.4.2 Secondary Research 42
8.4.3 Forecasting 42
8.4.4 Primary Research 45
8.4.5 Expert Panel Validation 45
8.5 Contact Us 45
8.6 Disclaimer 45
8.7 Sources 46

List of Table


Table 1: Influenza Vaccines, Global, Revenues ($bn), 20012009 8
Table 2: Influenza Vaccines, Global, Market Forecast ($bn), 20092017 9
Table 3: Comparison of the Major Marketed Products in Influenza Vaccines Market, 2010 20
Table 4: Influenza Vaccines Most Promising Vaccines Under Clinical Development, 2010 22
Table 5: Influenza Vaccines Phase III Clinical Pipeline, 2010 27
Table 6: Influenza Vaccines Phase II Clinical Pipeline, 2010 27
Table 7: Influenza Vaccines Phase I Clinical Pipeline, 2010 28
Table 8: Influenza Vaccines Preclinical Pipeline, 2010 29
Table 9: Influenza Vaccines Discovery Pipeline, 2010 29
Table 10: List of Discontinued Vaccines for Influenza, 2010 30
Table 11: Novartis, Infectious Diseases Vaccines Pipeline, 2010 33
Table 12: Novartis, Influenza Vaccines Pipeline, 2010 34
Table 13: GlaxoSmithKline, Infectious Diseases Vaccines Pipeline, 2010 35
Table 14: GlaxoSmithKline, Influenza Vaccines Pipeline, 2010 35
Table 15: Sanofi-aventis, Infectious Diseases Vaccines Pipeline, 2010 37
Table 16: Sanofi-aventis, Influenza Vaccines Pipeline, 2010 37
Table 17: CSL Limited, Infectious Diseases Vaccines Pipeline, 2010 38
Table 18: CSL Limited, Influenza Vaccines Pipeline, 2010 38
Table 19: MedImmune, Infectious Diseases Vaccines Pipeline, 2010 40
Table 20: MedImmune, Influenza Vaccines Pipeline, 2010 40

List of Chart


Figure 1: Influenza Vaccines, Global, Revenues ($bn), 20012009 8
Figure 2: Influenza Vaccines, Global, Market Forecast ($bn), 20092017 9
Figure 3: Opportunity and Unmet Need in the Influenza Vaccines Market, 2010 12
Figure 4: Strategic Competitor Assessment of the Influenza Vaccines Market, 2010 13
Figure 5: Technology Trends Analytic Framework, Influenza Vaccines, 2010 21
Figure 6: Technology Trends Analytic Framework, Influenza Vaccines Description, 2010 22
Figure 7: Influenza Vaccines Market Clinical Pipeline by Class of Vaccine, 2010 26
Figure 8: Influenza Vaccines Pipeline by Phase of Clinical Development, 2010 26
Figure 9: Implications For Future Market Competition in the Influenza Vaccines Market, 2010 31
Figure 10: Influenza Vaccines Market Clinical Pipeline by Company, 2010 32
Figure 11: GlobalData Market Forecasting Model, 2010 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *